Clinical Trial Detail

NCT ID NCT03094637
Title Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

myelodysplastic syndrome

Therapies

Azacitidine + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.